HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jimmunol.0901524v1 183/3/1514    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Google Scholar Articles by Segura, E. Articles by Villadangos, J. A. PubMed PubMed Citation Articles by Segura, E. Articles by Villadangos, J. A.

Cutting Edge: B220⁺CCR9^– Dendritic Cells Are Not Plasmacytoid Dendritic Cells but Are Precursors of Conventional Dendritic Cells¹

Elodie Segura^2,*,, June Wong^* and José A. Villadangos^2,*

^* Immunology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia; and INSERM Unité 932, Institut Curie, Paris, France

Mouse lymphoid organs contain two major subsets of dendritic cells (DC) that differ in their phenotype and functions: conventional DC (cDC) and plasmacytoid DC (pDC). Recently, it has been proposed that differential expression of CCR9 could distinguish functionally distinct pDC subsets. We show that B220⁺CCR9^– DC do not express classical pDC markers and have a developmental origin different from that of pDC. Furthermore, B220⁺CCR9^– DC do not secrete IFN- in response to CpG and, unlike pDC, can efficiently present exogenous Ags. Our results demonstrate that B220⁺CCR9^– DC do not represent a subset of pDC. After in vivo transfer, these cells down-regulate B220 expression and convert into the two major cDC subsets, showing that they are a developmental stage of cDC differentiation.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ This work was supported by the National Health and Medical Research Council of Australia (to J.A.V.), the Leukemia and Lymphoma Society (to J.A.V.), and Marie Curie Fellowships from the European Commission (to E.S.).

² Address correspondence and reprint requests to Dr. José A. Villadangos and Dr. Elodie Segura, Immunology Division, Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Victoria 3050, Australia. E-mail addresses: villadangos{at}wehi.edu.au and segura{at}wehi.edu.au

³ Abbreviations used in this paper: DC, dendritic cell; cDC, conventional DC; Ftl3L, Fms-like tyrosine kinase 3 ligand; int, intermediate; pDC, plasmacytoid DC; Flt3L.